Xylooligosaccharide oral liquid beneficial to zinc absorption and preparation method of xylooligosaccharide oral liquid

Abstract

The invention discloses xylooligosaccharide oral liquid beneficial to zinc absorption and a preparation method of the xylooligosaccharide oral liquid, and belongs to the technical field of food and health care products. The oral liquid is prepared by taking xylooligosaccharide, xylose and the zinc supplement as main components and supplementing with the buffering agent, the sweetening agent and the water, the prepared oral liquid can increase the absorption efficiency of the zinc supplement, and the zinc content in serum is increased to 29.2 mu moL / mL and is increased by 44.6% compared with that of single use of the zinc supplement; the intestinal barrier can be effectively improved, the intestinal absorption capacity is recovered, and the intestinal flora structure and abundance are improved.

Description

Technical Field

[0001] This invention belongs to the field of food and health product technology, specifically relating to an oral liquid of xylooligosaccharides that promotes zinc absorption and its preparation method. Background Technology

[0002] Zinc is an essential trace element for the human body, playing a crucial role in growth, development, and immunity. Zinc deficiency can lead to decreased taste and weakened immunity. In children, zinc deficiency can cause poor growth and development, as well as intellectual development problems. Zinc is currently believed to play important roles in physiological processes such as DNA replication, cell growth, wound healing, eye health, blood clotting, and thyroid function. However, the human body has a very high demand for zinc, and it is easily lost. Insufficient dietary intake, malabsorption, and increased requirements during specific physiological periods can easily lead to zinc deficiency. According to data from the Institute of Nutrition and Food Hygiene, Chinese Center for Disease Control and Prevention (between 2003 and 2019), the zinc deficiency rate among Chinese children and adolescents is as high as 60%, with daily zinc intake less than half of the World Health Organization's recommended intake.

[0003] Zinc is widely available, with shellfish, red meat, and organ meats being excellent sources. Most plant-based foods are low in zinc, while zinc-rich plant-based foods include nuts, cereal germ, and wheat bran. For specific populations, dietary zinc supplementation is slow and less effective; therefore, the development of zinc supplements can effectively reduce the bodily damage and health risks caused by zinc deficiency.

[0004] Zinc supplements come in many different forms, such as zinc gluconate, zinc acetate, zinc sulfate, zinc picolinate, zinc citrate, and zinc oroticate. However, inorganic and organic zinc supplements have poor zinc absorption. Protein zinc, on the other hand, is more expensive, and its product availability is currently limited. Summary of the Invention

[0005] [Technical Issues]

[0006] The technical problem this invention aims to solve is that current zinc supplements are expensive and have poor zinc absorption capacity.

[0007] [Technical Solution]

[0008] To address the aforementioned issues, this invention provides an oral liquid containing xylooligosaccharides that promotes zinc absorption, along with its preparation method. This invention utilizes xylooligosaccharide-mediated adjustment of gut microbiota structure to enhance the body's zinc absorption efficiency. The oral liquid of this invention is prepared using xylooligosaccharides and zinc supplements as main components, supplemented with buffers, sweeteners, and water, effectively improving zinc absorption efficiency.

[0009] This invention provides an oral liquid of xylooligosaccharides that promotes zinc absorption, which is made from the following ingredients by weight: 3-8 parts xylooligosaccharides, 0.5-2.5 parts zinc supplement, 0.2-0.5 parts buffer, 1-4 parts sweetener, and 50-150 parts water.

[0010] In a preferred embodiment of the present invention, xylooligosaccharide is obtained by enzymatic hydrolysis or extraction from one of the following: corn cob, sugarcane bagasse, cottonseed hull, wheat bran, wheat straw, rice straw, rice hull, and tree bark.

[0011] In a preferred embodiment of the present invention, the zinc supplement is one or more of zinc gluconate, zinc acetate, zinc sulfate, zinc pyridinecarboxylate, zinc citrate, and zinc oroticate.

[0012] In a preferred embodiment of the present invention, the buffer is one or more of sodium chloride and sodium bicarbonate.

[0013] In a preferred embodiment of the present invention, the sweetener is xylose.

[0014] The present invention also provides a method for preparing an oligosaccharide oral solution that promotes zinc absorption, specifically including the following steps: dissolving 3-8 parts of oligosaccharide in 50-150 parts of water, adding 1-4 parts of sweetener, stirring, and finally adding 0.2-0.5 parts of buffer and 0.5-2.5 parts of zinc supplement, adjusting the pH, homogenizing under high pressure, sterilizing and dispensing to obtain an oligosaccharide oral solution that promotes zinc absorption.

[0015] In a preferred embodiment of the present invention, the pH is adjusted to 3.7-6.9.

[0016] As a preferred embodiment of the present invention, the parameters for high-pressure homogenization are: 25-40 Hz, 50-100 bar.

[0017] [Beneficial Effects]

[0018] This invention uses xylooligosaccharides and zinc supplements as the main components, supplemented with buffers, sweeteners, and water, to prepare an oral solution of xylooligosaccharides that promotes zinc absorption. This is mainly because xylooligosaccharides can regulate the structure and metabolism of intestinal flora, thereby improving the zinc transport efficiency of intestinal cells. The prepared oral solution can increase the absorption efficiency of zinc supplements, increasing the serum zinc content to 29.2 μmol / mL, which is 44.6% higher than that of using zinc supplements alone; it can also effectively improve the intestinal barrier, restore intestinal absorption capacity, and improve the structure and abundance of intestinal flora. Attached Figure Description

[0019] Figure 1 This is a graph showing the effect of the oral liquid of Example 1 of the present invention on zinc absorption;

[0020] Figure 2This is a diagram showing the effect of the oral liquid of Example 1 of the present invention on the intestinal barrier;

[0021] Figure 3 Figure A shows the effect of the oral liquid of Example 1 of the present invention on the intestinal flora. Figure B is a Venn diagram of species, showing the similarity and specificity of OTU composition among the groups; Figure C is a distribution map of bacterial species at the phylum level; Figure D is a heatmap of bacterial abundance at the genus level, where Ctrl is the normal group, ZnD is the zinc deficiency diet-induced model group, ZnSO4 is the zinc sulfate supplementation group, X is the xylose supplementation group, and XOS is the xylooligosaccharide supplementation group. Detailed Implementation

[0022] The present invention will be further described below with reference to embodiments. However, the described embodiments are merely some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0023] Unless otherwise specified, the instruments, reagents, and materials used in the following embodiments are all conventional instruments, reagents, and materials already available in the prior art and can be obtained through legitimate commercial channels. Unless otherwise specified, the experimental methods and detection methods used in the following embodiments are all conventional experimental methods and detection methods already available in the prior art.

[0024] In the following examples, one part by weight is 5g.

[0025] Zinc supplement zinc sulfate (Merck, M10888302).

[0026] Example 1

[0027] This embodiment provides an oral liquid containing xylooligosaccharides that promotes zinc absorption. By weight, the oral liquid formulation includes 6 parts xylooligosaccharides, 1 part zinc supplement (zinc sulfate), 0.2 parts sodium chloride buffer, 3 parts xylose sweetener, and 100 parts water.

[0028] The specific method for preparing the oral liquid is as follows:

[0029] A method for preparing an oligosaccharide oral solution that promotes zinc absorption is as follows: Weigh 6 parts of oligosaccharide, dissolve it in 100 parts of water, add 3 parts of xylose, place it in a constant temperature water bath at 30℃, stir and dissolve for 50-70 minutes, add 1 part of zinc supplement and 0.2 parts of buffer sodium chloride, mix and stir, adjust the pH to 5.9, mix at room temperature for 4 hours to ensure thorough mixing, finally homogenize under high pressure (25-40HZ, 100 bar), sterilize and dispense to obtain an oligosaccharide oral solution that promotes zinc absorption.

[0030] Example 2

[0031] This embodiment provides an oral liquid containing xylooligosaccharides that promotes zinc absorption. By weight, the oral liquid formulation includes 3 parts xylooligosaccharides, 1.4 parts zinc supplement (zinc sulfate), 0.3 parts sodium chloride buffer, 4 parts xylose sweetener, and 100 parts water.

[0032] The specific method for preparing the oral liquid is as follows:

[0033] A method for preparing an oligosaccharide oral solution that promotes zinc absorption is as follows: Weigh 3 parts of oligosaccharide, dissolve it in 100 parts of water, add 4 parts of xylose, place it in a constant temperature water bath at 30℃, stir and dissolve for 50-70 minutes, add 1.4 parts of zinc supplement and 0.3 parts of buffer sodium chloride, mix and stir, adjust the pH to 5.9, mix at room temperature for 4 hours to ensure thorough mixing, finally homogenize under high pressure (25-40HZ, 100 bar), sterilize and dispense to obtain an oligosaccharide oral solution that promotes zinc absorption.

[0034] Example 3

[0035] This embodiment provides an oral liquid containing xylooligosaccharides that promotes zinc absorption. By weight, the oral liquid formulation includes 4 parts xylooligosaccharides, 1.6 parts zinc supplement (zinc sulfate), 0.25 parts sodium bicarbonate buffer, 2 parts xylose sweetener, and 100 parts water.

[0036] The specific method for preparing the oral liquid is as follows:

[0037] A method for preparing an oligosaccharide oral solution that promotes zinc absorption is as follows: Weigh 4 parts of oligosaccharide, dissolve it in 100 parts of water, add 2 parts of xylose, place it in a constant temperature water bath at 30℃, stir and dissolve for 50-70 minutes, add 1.6 parts of zinc supplement and 0.25 parts of sodium bicarbonate buffer, mix and stir, adjust the pH to 5.9, mix at room temperature for 4 hours to ensure thorough mixing, finally homogenize under high pressure (25-40HZ, 100 bar), sterilize and dispense to obtain an oligosaccharide oral solution that promotes zinc absorption.

[0038] Comparative Example 1

[0039] The oral liquid raw material formula, by weight, includes 1 part xylooligosaccharide, 1 part zinc supplement (zinc sulfate), 0.2 parts sodium chloride buffer, 3 parts xylose sweetener, and 100 parts water.

[0040] The specific method for preparing the oral liquid in this comparative example is as follows:

[0041] Weigh 1 part xylooligosaccharide and dissolve it in 100 parts water. Add 3 parts xylose and place it in a 30°C constant temperature water bath. Stir and dissolve for 50-70 minutes. Add 1 part zinc supplement (zinc sulfate) and 0.2 parts sodium chloride buffer. Mix and stir to adjust the pH to 5.9. Mix at room temperature for 4 hours to ensure thorough mixing. Finally, homogenize under high pressure (25-40 Hz, 100 bar), sterilize, and dispense to obtain the oral liquid.

[0042] Comparative Example 2

[0043] The oral liquid formula, by weight, includes 1 part zinc supplement (zinc sulfate), 0.2 parts sodium chloride buffer, 3 parts xylose sweetener, and 100 parts water.

[0044] The specific method for preparing the oral liquid in this comparative example is as follows:

[0045] Weigh 3 parts xylose and dissolve them in 100 parts water. Place the solution in a 30°C constant temperature water bath and stir for 50-70 minutes. Add 1 part zinc supplement (zinc sulfate) and 0.2 parts sodium chloride buffer. Mix and stir to adjust the pH to 5.9. Mix at room temperature for 4 hours to ensure thorough mixing. Finally, homogenize under high pressure (25-40 Hz, 100 bar), sterilize, and dispense to obtain an oral liquid.

[0046] Comparative Example 3

[0047] The oral liquid formula, by weight, includes 6 parts β-glucan, 1 part zinc supplement (zinc sulfate), 0.2 parts sodium chloride buffer, 3 parts xylose sweetener, and 100 parts water.

[0048] The specific method for preparing the oral liquid in this comparative example is as follows:

[0049] Weigh 6 parts of β-glucan, dissolve it in 100 parts of water, add 3 parts of xylose, place it in a constant temperature water bath at 30℃, stir and dissolve for 50-70 minutes, add 1 part of zinc supplement (zinc sulfate) and 0.2 parts of buffer sodium chloride, mix and stir, adjust the pH to 5.9, mix at room temperature for 4 hours to ensure thorough mixing, finally homogenize under high pressure (25-40HZ, 100 bar), sterilize and dispense to obtain a β-glucan oral solution.

[0050] Performance evaluation of the oral liquid of the present invention

[0051] Oral zinc absorption assay in mice:

[0052] Four-week-old male C57BL / 6 mice were routinely acclimatized for one week, and then grouped according to experimental requirements. The mice were randomly divided into four groups: normal group, model group, zinc sulfate supplementation control group, experimental group, control group 1, control group 2, and control group 3. The normal group was fed a regular diet via random feeding. The model group was fed a low-zinc diet (9 mg / kg feed) to simulate zinc deficiency via random feeding. The zinc sulfate supplementation control group was fed a low-zinc diet (9 mg / kg feed) and simultaneously administered ZnSO4 (zinc sulfate salt dissolved in deionized water at a concentration of 55.5 mg / mL) via gavage for 30 days, with a zinc content of 277.5 mg / kg bw. The experimental group was fed a low-zinc diet (9 mg / kg feed) and simultaneously administered an oral solution containing xylooligosaccharides (Example 1) via gavage (0.5 mg / animal / day), with the same zinc content of 277.5 mg / kg bw, for 30 days. The control group was fed a low-zinc diet (9 mg / kg feed) and administered an oral solution (Comparative Example 1) via gavage, with the same zinc content of 277.5 mg / kg bw, for 30 days. The control group 1 was fed a low-zinc diet (9 mg / kg feed) and administered an oral solution via gavage (Comparative Example 1), with the same zinc content of 277.5 mg / kg bw. Group 1 was fed a low-zinc diet (9 mg / kg feed) for 30 days. Group 2 was fed an oral solution via gavage (Comparative Example 2) with the same zinc content of 277.5 mg / kg bw for 30 days. Group 3 was fed a low-zinc diet (9 mg / kg feed) with oral solution via gavage (Comparative Example 3) with the same zinc content of 277.5 mg / kg bw for 30 days. Mice were weighed daily, and their body weight and feces were collected. At the end of the experiment, blood samples, intestinal tissue, and feces were collected from the mice for further analysis.

[0053] Serum zinc levels were determined using a biological zinc assay kit (Wuhan Elite Biotechnology, E-BC-K137-M). The spectrophotometer was preheated for 30 minutes, the wavelength was adjusted to 620 nm, and the instrument was zeroed with distilled water. The standard solution was removed in advance, allowed to thaw completely at room temperature, and then mixed thoroughly. The standard solution and test solution were added sequentially to a 1 mL EP tube. After thorough mixing, the mixture was incubated at 25°C for 10 minutes. 200 μL was then pipetteed into a microquartz cuvette / 96-well plate, and the absorbance was measured at 620 nm.

[0054] Depend on Figure 1The results showed that the average zinc content in the serum of the model group was 20.2 μmol / mL. The use of xylooligosaccharide oral solution (Example 1) in the experimental group effectively increased the absorption efficiency of zinc supplements in mice, raising the average serum zinc content to 29.2 μmol / mL, which was 44.6% higher than the control group. The average zinc content in the serum of the control groups 1-3 were 21.8 μmol / mL, 20.7 μmol / mL, and 21.4 μmol / mL, respectively, showing no significant difference compared to the model group.

[0055] A segment of intestinal tissue was taken from mice, rinsed with PBS, fixed in 4% paraformaldehyde, and then routinely dehydrated, embedded, sectioned, and stained with hematoxylin and eosin (HE). The pathological structure of the intestinal tissue was observed using an optical microscope.

[0056] like Figure 2 As shown, the level of intestinal damage in colonic tissue was detected by tissue sections and HE staining. In the model (zinc-deficient) group, the colonic tissue structure of mice was disordered, with some samples showing complete loss of colonic morphology and destruction or absence of the small intestinal crypt-villi structure. The intestinal morphology of mice in the zinc sulfate supplementation control group showed no significant improvement. However, after intervention with xylooligosaccharides, the colonic tissue morphology of mice was significantly improved, and the intestinal villi and epithelial structure remained intact. Therefore, the xylooligosaccharide oral solution of this invention can effectively improve the intestinal barrier in zinc-deficient mice and restore their intestinal absorption capacity.

[0057] Microbial diversity analysis was conducted by GNEWIZ Biotechnology Co., Ltd. During dissection, colonic contents were collected from mice, flash-frozen in liquid nitrogen, and then preserved and transported on dry ice for 16S rRNA gene sequencing of the gut microbiota to analyze changes in the mouse gut microbiota. Total bacterial DNA was extracted and sequenced. DNA was amplified targeting the V4 region of bacterial 16S rDNA and pyrosequencing (2×250) was performed on the Illumina MiSeq platform. Sample reading was performed using mothur v1.32. Chimeric sequences were removed using USEARCH software according to the UCHIME algorithm. Microbial diversity was analyzed using QIIME software and Python scripts. Purified PCR products were used for Illumina PE300 library construction and sequencing. Reads were quality-controlled and filtered. OTU clustering analysis was performed on the quality-controlled assembled sequences based on 97% similarity. Based on the OTU clustering analysis results, diversity index analysis and sequencing depth detection were performed. Statistical analysis of community structure was conducted at various taxonomic levels based on taxonomic information.

[0058] Depend on Figure 3The results showed that xylooligosaccharide (experimental group) was more similar to the normal group in terms of OTU similarity, but significantly different from the zinc-deficient model group. Further analysis of the gut microbiota composition revealed that at the phylum level, the relative abundance of Firmicutes in xylooligosaccharide-treated mice was significantly lower than in the normal group, while the relative abundance of Verrucomicrobia and Bacteroidetes was significantly upregulated, and the Firmicutes / Bacteroidetes ratio was downregulated. The relative abundance of Akkermansia muciniphila in xylooligosaccharide-treated mice was also significantly higher than in the model group. Furthermore, xylooligosaccharide treatment upregulated the abundance of Bacteroides (Parabacteroides distasonis, Bacteroides acidifaciens). This indicates that xylooligosaccharide oral solution can effectively improve the structure and abundance of gut microbiota in zinc-deficient mice. Among them, bacteria such as *Pseudomonas diffusa*, *Bacteroides acidophilus*, and *Ackermania myxotroph* are closely related to the intestinal absorption capacity of minerals and the intestinal barrier function.

[0059] The results of the above embodiments show that the xylooligosaccharide oral solution provided by the present invention, which is beneficial to zinc absorption, can promote the absorption of zinc ions and has a significant absorption effect.

[0060] The embodiments provided above are not intended to limit the scope of the invention, nor are the described steps intended to limit the order of execution. Any obvious modifications made to the invention by those skilled in the art based on existing common knowledge also fall within the scope of protection defined by the claims.

Claims

1. An oral solution of xylooligosaccharides that promotes zinc absorption, characterized in that, It is made from the following ingredients by weight: 3-8 parts xylooligosaccharide, 0.5-2.5 parts zinc supplement, 0.2-0.5 parts buffer, 1-4 parts sweetener, and 50-150 parts water.

2. The oral liquid according to claim 1, characterized in that, It is made from the following ingredients by weight: 6 parts xylooligosaccharide, 1 part zinc supplement, 0.2 parts buffer, 3 parts sweetener, and 100 parts water.

3. The oral liquid according to claim 1, characterized in that, It is made from the following ingredients: 3 parts xylooligosaccharide, 1.4 parts zinc supplement, 0.3 parts buffer, 4 parts sweetener, and 100 parts water.

4. The oral liquid according to claim 1, characterized in that, It is made from the following ingredients: 4 parts xylooligosaccharide, 1.6 parts zinc supplement, 0.25 parts buffer, 2 parts sweetener, and 100 parts water.

5. The oral liquid according to claim 1, characterized in that, Zinc supplements are one or more of the following: zinc gluconate, zinc acetate, zinc sulfate, zinc pyridinecarboxylate, zinc citrate, and zinc oroticate.

6. The oral liquid according to claim 1, characterized in that, The buffer is one or more of sodium chloride and sodium bicarbonate.

7. The oral liquid according to claim 1, characterized in that, The sweetener is xylose.

8. The method for preparing the oral liquid according to any one of claims 1-7, characterized in that, The specific steps include: dissolving 3-8 parts of xylooligosaccharide in 50-150 parts of water, adding 1-4 parts of sweetener, stirring, and finally adding 0.2-0.5 parts of buffer and 0.5-2.5 parts of zinc supplement, adjusting the pH, homogenizing under high pressure, sterilizing and dispensing to obtain the oral liquid.

9. The preparation method according to claim 8, characterized in that, Adjust the pH to 3.7-6.

9.

10. The preparation method according to claim 8, characterized in that, The parameters for high-pressure homogenization are: 25-40 Hz, 50-100 bar.

Images